




# PHARMACEUTICAL 2018

ENDONOVO THERAPEUTICS INC.  
Rank 317 of 342





RealRate

# PHARMACEUTICAL 2018

## ENDONOVO THERAPEUTICS INC. Rank 317 of 342

The relative strengths and weaknesses of ENDONOVO THERAPEUTICS INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ENDONOVO THERAPEUTICS INC. compared to the market average is the variable Intangible Assets, increasing the Economic Capital Ratio by 123% points. The greatest weakness of ENDONOVO THERAPEUTICS INC. is the variable Assets, Current, reducing the Economic Capital Ratio by 207% points.

The company's Economic Capital Ratio, given in the ranking table, is -290%, being 336% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	111
Cost of Goods Sold	0
Intangible Assets	4,500
Liabilities, Current	0
Liabilities, Non-Current	0
Other Assets	0
Other Compr. Net Income	0
Other Expenses	4,604
Other Liabilities	14,163
Other Net Income	-6,206
Other Revenues	0
Property and Equipment	1.1
Research and Development	0
Selling, General and Administrative Expense	0

Output Variable	Value in 1000 USD
Assets	4,612
Liabilities	14,163
Expenses	4,604
Revenues	0
Stockholders Equity	-9,550
Net Income	-10,810
Comprehensive Net Income	-10,810
Economic Capital Ratio	-290%